Connect with us

Caribbean News

Jamaican Scientist Excel

Published

on

#Jamaica, November 2, 2017 – Kingston – Within recent years, Jamaicans have been recording significant achievements in the field of science, locally, regionally and globally, through endeavors in research and development.  Notable among them are Executive Chairman of the Eden Group of Companies, Dr. Henry Lowe; Senior Lecturer, Faculty of Science and Technology and Director of the Natural Products Institute at the University of the West Indies (UWI) Mona Campus, Dr. Rupika Delgoda; and Lecturer in the UWI’s Medical Science Faculty, Dr. Simone Badal.

Dr. Lowe spearheaded the landmark development of the drug ‘Chrysoeriol’, a derivative of cannabis (ganja) for treating acute myeloid leukaemia (AML).   AML is classified as a rare cancer of the myeloid line of blood cells, characterised by rapidly growing abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. It is the most common acute leukaemia affecting adults, and its incidence increases with age.

Dr. Lowe and his diligent team of researchers were granted coveted United States Food and Drug Administration (FDA) Orphan Drug Designation earlier this year.  This is awarded to novel drugs or biologics that treat rare diseases or conditions affecting less than 200,000 patients, as is the case with AML. It qualifies the developer for a seven-year period of US marketing exclusivity upon FDA approval of the drug.

Other benefits include tax credits for clinical research qualification for annual grant funding, clinical trial design assistance, and the waiving of filing fees under the Prescription Drug User Fee Act.

Speaking at a ceremony in Kingston earlier this year, Dr. Lowe said the Orphan Drug designation, a first for the island and wider Caribbean, “places us (Jamaica) in (the) very enviable position (of being part of) a very exclusive club of a few countries… involved in drug research, innovation and development”.

These, he pointed out, include nations in North America, mainly the United States, and Europe.

Consequent on the award, the Eden Gardens Group, which includes US-based research and development facility, Flavocure Biotech, and the Biotech R&D Institute, situated on the UWI’s Mona Campus, will benefit from grant funding totaling US$250,000 for each of the next three years to complete the work on Chrysoeriol’s development.  He indicated that based on the work undertaken, thus far, “there is still a few million dollars (more that needs) to be spent to get us to market”.

Against this background, Dr. Lowe said there is a potential US$3.5 million in additional FDA funding support that may be forthcoming to fast-track that work, adding that “we are going after it”.

“Normally, when you get to the stage we have reached, it takes another five to 12 years to go to market.   Here, we can go to market between two to three years, if not earlier… but we have to move quickly,” he added.

Prime Minster, the Most Hon. Andrew Holness, lauded Dr. Lowe, noting that the Orphan Drug designation was a “practical manifestation of (the) theory of research and development stimulating innovation which drives economic growth”.

“This achievement resulting from combining knowledge, technology and entrepreneurship leading to innovation by Dr. Lowe, is just reward for his hard work and dedication to science,” Mr. Holness further said.

Science, Energy and Technology Minister, Dr. the Hon. Andrew Wheatley, also praised Dr. Lowe and his team, noting that “as a scientist, I can say without any reservation that to get to this point took some level of commitment and belief in this particular work”.

Dr. Wheatley said the FDA award underlined the fact that “we have that inherent intellectual capacity to do quality research and development in Jamaica”.

Portfolio Minister, Hon. Karl Samuda, said Chrysoeriol “will certainly have a major impact on the development of the medicinal cannabis industry, once again putting Jamaica at the forefront of the scientific development of the industry”.

“Jamaica has now proven to the world that we have the capabilities to be a world-class player, not only in science and technology, but also in drug research and development,” he added.

For Drs. Delgoda and Badal, who co-authored the text ‘Pharmacognosy: Fundamentals, Applications and Strategy’, the publication represents a crowning moment in their careers.

Pharmacognosy is the study of medicinal drugs derived from plants and other natural sources, and the textbook is expected to be integral to tertiary training delivery in the subject area.

Dr. Badal said the project represents the combined efforts of a number of distinguished scholars around the world.  She explained that the idea to publish the text partly stemmed from her concerns with the quality of material that was available to her while teaching pharmacognosy at another tertiary institution.  Dr. Badal said she discussed the matter with her family, who suggested that she give consideration to publishing a textbook.

Noting that the idea was “simple yet profound”, Dr. Badal said “working in conjunction with divinely orchestrated events, (plus) the value of the inputs of my co-editor (Dr. Delgoda) and several other authors and reviewers, have birthed this textbook that we celebrate”.

Dr. Delgoda indicated that 28 of the authors came from the Caribbean, of which 24 were based at the UWI’s Mona Campus, noting that “without their significant contributions, this book would not have been possible”.   She also acknowledged the “sustained collaborations and outstanding research” in natural products by UWI Mona-based researchers, “whose work actually inspired many aspects of this book.”   She further said that “based on the capacity that we have here, on Campus, this book will become very useful”.

UWI Pro Vice-Chancellor and UWI Mona Principal, Professor Archibald McDonald, said the institution is proud of the lecturers’ achievement, noting that the institution “is always pleased to support the work of academics and researchers who are making significant contributions to their subject areas.   He said the text brings to the fore interesting and new research and insights into the dynamics of pharmacognosy and the development of this branch of science.

“The book provides a comprehensive background into what pharmacognosy is, and then delves into a discussion into its role in traditional medicine, how it is used in botany and the development of plant- and animal-based pharmaceuticals, just to mention a few highlights of the work,” the Pro Vice-Chancellor noted.

Against this background, Professor McDonald said he is optimistic that the text “will certainly help to fill yet another important knowledge gap in pharmaceutical and medical research”.

Dr. Wheatley lauded Drs. Badal and Delgoda while emphasizing the Government’s commitment to capitalizing on the benefits to be derived from the “rapidly growing” nutraceutical industry, this, he said, by harnessing Jamaica’s vast plant resources.   He said the text “is a (pivotal) tool that can be used to guide the (utilization) of our natural resources in a sustainable manner to catalyze Jamaica’s economic and social enhancement”.

Distinguished State University of New York Professor, Gene Morse, is the publication’s chief reviewer, and there are several local and international contributors to the publication.

By: Douglas McIntosh (JIS)

 

 

 

 

Continue Reading

Caribbean News

The $3 Billion Handshake

Published

on

By Deandrea Hamilton | Editor

 

September 28, 2026 – Wall Street initially flinched at the $3-billion handshake. But in a matter of days, it was smoother sailing.

Perhaps the bigger Caribbean business story is not what Sandals Resorts International is getting from the deal. It is who is writing the cheque — and what that says about what Gordon “Butch” Stewart built.

As reports of Royal Caribbean Group’s Sandals deal circulated Tuesday, RCL shares plunged 6.14 percent from Monday’s $250.25 close to $234.89, on sharply elevated trading.

When the agreement became official Wednesday — approximately $3 billion for a 50 percent equity interest in Sandals and Beaches Resorts — shares slipped another 1.95 percent to $230.30 and touched $222.22 intraday. Investors were digesting both the size of the investment and committed debt financing secured through Morgan Stanley.

But by Thursday, RCL rebounded 3.77 percent, with shares continuing their recovery Friday to finish the week around $243. Analysts were also looking ahead: JPMorgan reportedly raised its RCL price target from $345 to $394, while Citi placed the company on a 90-day positive catalyst watch.

And just who is RCL?

Royal Caribbean Group is a global vacation giant, publicly traded on the New York Stock Exchange with a market value of roughly $65 billion. Its portfolio includes Royal Caribbean International, Celebrity Cruises and Silversea, alongside private destinations and an expanding vacation platform.

So when a company of that scale commits $3 billion for only half of Sandals and Beaches Resorts, the transaction puts a striking financial marker on one of the Caribbean’s greatest home-grown hospitality success stories.

The deal, expected to close in early 2027, creates a 50-50 partnership with the Stewart family and takes Royal Caribbean deeper into the all-inclusive resort business.

Butch Stewart started Sandals in Jamaica in 1981 believing a Caribbean company could compete with the world’s best.

Forty-five years later, one of the world’s biggest vacation companies is prepared to pay $3 billion just to own half of what he built.

Now that’s the handshake that does more than seal a deal — it cements a legacy.

Continue Reading

Caribbean News

Royal Caribbean Group and Sandals Resorts Announce Landmark Partnership to Accelerate Their Leading Vacation Experiences

Published

on

Royal Caribbean Group Investment to Advance Sandals and Beaches’ Growth and Broaden the Group’s Vacation Portfolio

Montego Bay, Jamaica and Miami, September 24, 2026 – Royal Caribbean Group (NYSE: RCL) and Sandals Resorts today announced the signing of an agreement to form a partnership in the all-inclusive resort space with a 50% investment from Royal Caribbean Group.  Building on Sandals and Beaches Resorts’ more than four decades of leadership in Caribbean hospitality, the joint venture will create new opportunities for continued resort growth while broadening the experiences across Royal Caribbean Group’s vacation platform.

The partnership brings together two of the travel industry’s most celebrated vacation companies, pairing Sandals and Beaches’ all-inclusive resort expertise with Royal Caribbean Group’s vacation platform, including industry-leading brands – Royal Caribbean, Celebrity Cruises and Silversea – a portfolio of private destinations, new river cruising offering, and an industry-first loyalty program. United in a shared history in the Caribbean and connected by a love for their communities, the companies will offer travelers an unparalleled collection of cruise, private destination and resort experiences, serving guests across more vacation occasions and establishing their undisputed leadership in Caribbean vacations.

The joint venture expands Royal Caribbean Group into an adjacent vacation category, growing its participation in the approximately $2 trillion global vacation market, and meets the growing global demand for Sandals and Beaches Resorts by accelerating their expansion. The partnership will include Sandals and Beaches’ collection of premier all-inclusive properties across the Caribbean, and the companies will explore opportunities to broaden distribution, deepen guest engagement, and make it easier for travelers to discover vacation experiences offered across both portfolios.

“For nearly 60 years, we’ve reimagined what a vacation can be, constantly expanding the ways we inspire our guests to explore, connect and create lifelong memories,” said Jason Liberty, Chairman and CEO, Royal Caribbean Group. “We have been building a vacation platform that brings joy to millions of people around the world and creates meaningful relationships that last with our guests. Our partnership with Sandals and Beaches Resorts is an important next step on that journey – bringing together two iconic leading vacation companies to further strengthen and grow one of the most admired resort portfolios in the world. The Stewart family has created powerful and beloved brands, and we are honored to build on that legacy. Together, we see tremendous opportunity to expand the reach of Sandals and Beaches Resorts and continue turning the vacation of a lifetime into a lifetime of vacations.”

“My father, Gordon ‘Butch’ Stewart, founded Sandals Resorts with the belief that a company built in the Caribbean could stand on the world stage alongside the most respected names in hospitality. Today is proof of how far that vision can go,” said Adam Stewart, Executive Chairman of Sandals Resorts and Beaches Resorts. “This partnership is the natural next step in building on that conviction. It gives us the ability to grow faster with a partner that shares our values of exceptional hospitality, long-term investment, and the power of enduring brands. Together, we will introduce more guests to Sandals and Beaches Resorts while creating even more extraordinary experiences for those who have made our resorts part of their lives for decades.” Stewart added, “As we continue to grow, we will remain true to what has always defined us: delivering authentic vacations that exceed expectations while creating opportunities for our team members, travel advisor partners and the communities we call home. The future has never been brighter, and I know this moment would make my father incredibly proud.”

The joint venture will be governed by a board under the shared leadership of Stewart and Liberty. Stewart will maintain a leadership role in guiding the company’s long-term strategic growth as Executive Chairman of Sandals and Beaches Resorts. Existing reservations, loyalty programs, resort operations and cruise operations will continue as usual, with the partnership bringing additional resources to support future opportunities.

Under the terms of the agreement, Royal Caribbean Group will acquire a 50% equity interest in Sandals and Beaches Resorts for approximately $3 billion, representing a forward EBITDA multiple of approximately 10x.  Royal Caribbean Group has secured committed debt financing from Morgan Stanley to fund the investment.  The transaction is expected to close in early 2027, subject to customary approvals and closing conditions, and is expected to be accretive to earnings next year.

BofA Securities and PJT Partners acted as financial advisors, and Latham & Watkins and Jones Day acted as legal advisors to the Sandals Group. Perella Weinberg Partners and Morgan Stanley acted as financial advisors and Kirkland & Ellis LLP acted as legal advisor to Royal Caribbean Group.

PHOTO CAPTION: Jason Liberty, Chairman and CEO of Royal Caribbean Group, and Adam Stewart, Executive Chairman of Sandals Resorts, mark the signing of an agreement to form a landmark partnership that expands Royal Caribbean Group into the all-inclusive resort space and supports the future growth of Sandals and Beaches Resorts. The signing took place at Royal Caribbean Group’s new headquarters in Miami, with the city’s skyline in the background.

Continue Reading

Caribbean News

Royal Caribbean Signs US$3-Billion Deal for Half of Sandals and Beaches

Published

on

The Caribbean tourism deal first reported as a possibility on Tuesday is now a signed agreement. Royal Caribbean Group plans to pay approximately US$3 billion for a 50% stake in Sandals and Beaches Resorts, putting the value of the business at about US$6 billion. The purchase is expected to close in early 2027, subject to approvals.

Founded in Jamaica by the late Gordon “Butch” Stewart in 1981, the resort business has a presence across nine Caribbean destinations, including Jamaica, The Bahamas and Turks and Caicos. Sandals has described its workforce as nearly 20,000 people, most of them Caribbean nationals.

“My father, Gordon ‘Butch’ Stewart, founded Sandals Resorts with the belief that a company built in the Caribbean could stand on the world stage alongside the most respected names in hospitality,” said Adam Stewart in the announcement carried by PR Newswire. He will remain executive chairman, while the Stewart family retains a stake. The companies say existing reservations and resort operations will continue as usual.

Continue Reading

FIND US ON FACEBOOK

TRENDING